Voiosu Theodor, Bălănescu Paul, Benguş Andreea, Voiosu Andrei, Baicuş Cristian Răsvan, Barbu Maria, Ladaru Anca, Nitipir Cornelia, Mateescu Bogdan, Diculescu Mircea, Voiosu Radu
Clin Lab. 2014;60(3):505-10. doi: 10.7754/clin.lab.2013.130333.
Endocan is a marker of angiogenesis previously studied in various types of cancer and inflammatory conditions. Its expression is influenced by vascular endothelial growth factor A (VEGF A) and tumor necrosis factor alpha (TNF alpha), cytokines involved in pathogenetic pathways in inflammatory bowel disease (IBD). The aim of this study was to determine whether serum endocan levels were increased in IBD patients.
We conducted an exploratory pilot study. Serum endocan levels were determined in a group of 33 consecutive IBD patients from an observational cohort study ongoing at Colentina Hospital and compared to levels determined in two control groups: healthy controls and stage IV cancer patients.
Endocan levels were significantly higher in the IBD group as compared to both healthy controls (p < 0.001) and cancer patients (p < 0.01). There was no correlation found between endocan levels and disease activity as assessed by clinical or endoscopical activity scores.
There is a potential role for endocan in future biomarker studies in IBD patients.
内脂素是一种血管生成标志物，此前已在多种类型的癌症和炎症性疾病中进行过研究。其表达受血管内皮生长因子A（VEGF A）和肿瘤坏死因子α（TNFα）影响，这两种细胞因子参与炎症性肠病（IBD）的发病机制。本研究的目的是确定IBD患者血清内脂素水平是否升高。
我们进行了一项探索性初步研究。在科伦蒂纳医院正在进行的一项观察性队列研究中，对33例连续的IBD患者测定血清内脂素水平，并与两个对照组（健康对照组和IV期癌症患者）的测定水平进行比较。
与健康对照组（p < 0.001）和癌症患者（p < 0.01）相比，IBD组的内脂素水平显著更高。通过临床或内镜活动评分评估，未发现内脂素水平与疾病活动之间存在相关性。
内脂素在IBD患者未来的生物标志物研究中可能具有一定作用。
